According to 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [34], young women with ER+ ABC should have adequate ovarian suppression or ablation (OFS/OFA) and then be treated in the same way as postmenopausal women with endocrine agents with or without targeted therapies. This evidence concerns the gene ESR1 and breast cancer.